Tanager Wealth Management LLP Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Tanager Wealth Management LLP grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,008 shares of the medical research company’s stock after acquiring an additional 37 shares during the quarter. Tanager Wealth Management LLP’s holdings in Thermo Fisher Scientific were worth $624,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of TMO. International Assets Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 76,051.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company’s stock valued at $876,152,000 after buying an additional 1,414,556 shares in the last quarter. Monte Financial Group LLC raised its position in Thermo Fisher Scientific by 2.7% during the third quarter. Monte Financial Group LLC now owns 2,213 shares of the medical research company’s stock valued at $1,369,000 after purchasing an additional 58 shares during the period. Courier Capital LLC boosted its holdings in shares of Thermo Fisher Scientific by 798.9% in the 3rd quarter. Courier Capital LLC now owns 8,405 shares of the medical research company’s stock worth $5,199,000 after purchasing an additional 7,470 shares during the period. Sterling Investment Counsel LLC increased its position in shares of Thermo Fisher Scientific by 10.6% during the 3rd quarter. Sterling Investment Counsel LLC now owns 2,169 shares of the medical research company’s stock valued at $1,342,000 after purchasing an additional 207 shares during the last quarter. Finally, Greenleaf Trust raised its holdings in Thermo Fisher Scientific by 0.9% during the 3rd quarter. Greenleaf Trust now owns 12,406 shares of the medical research company’s stock valued at $7,674,000 after buying an additional 115 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 1.7 %

Shares of NYSE:TMO opened at $576.49 on Thursday. The company has a market capitalization of $220.22 billion, a PE ratio of 35.76, a P/E/G ratio of 3.75 and a beta of 0.77. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $627.88. The business’s fifty day simple moving average is $607.04 and its 200-day simple moving average is $584.39.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the company posted $5.15 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at $1,108,408.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares in the company, valued at approximately $1,108,408.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,860,920.55. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock valued at $14,094,292 in the last 90 days. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of several recent analyst reports. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Stephens started coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target on the stock. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $655.50.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.